Hepatotoxicity from pyrazinamide based anti-tuberculous therapy: protective effect from isoniazid and HIV infection? | Thorax

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Article Text

Miscellaneous

Hepatotoxicity from pyrazinamide based anti-tuberculous therapy: protective effect from isoniazid and HIV infection?

Free

A E Boyd

Research Registrar, Homerton University Hospital NHS Trust, UK; aileen.boyd@homerton.nhs.uk

https://doi.org/10.1136/thx.2004.la0139

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

▴ Van Hest R, Baars H, Kik S, et al. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin Infect Dis2004;39:488–96

OpenUrl Abstract/FREE Full Text

▴ Gordin FM, Cohn DL, Matts JP, et al. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? Clin Infect Dis2004;39:561–5

OpenUrl Abstract/FREE Full Text

In 1999 the American Thoracic Society (ATS), the Centers for Disease Control and Prevention (CDC), and the Infectious Diseases Society of America (IDSA) endorsed a 2 month daily regimen of rifampin and pyrazinamide (2RZ) for the treatment of latent tuberculosis (TB) infection. This recommendation followed a prospective randomised trial in HIV infected persons showing that 2RZ had similar efficacy and safety to a 12 month regimen of daily …